Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Guilford (GLFD) - Steadily Rising -- Ignore unavailable to you. Want to Upgrade?

To: LLCF who wrote (276)	4/23/1999 1:02:00 PM
From: sim1	Read Replies (1) \| Respond to of 496

Some panic shots from their encircled wagons? If you're referring to the 100K repurchase in early March... ''This investment by Guilford and members of our senior management team signifies our strong confidence in Guilford's future prospects,'' remarked Dr. Craig R. Smith, President and CEO of Guilford. ''We are pleased to be able to take advantage of this opportunity.''

To: LLCF who wrote (276)	4/23/1999 5:19:00 PM
From: Steve	Read Replies (1) \| Respond to of 496

The rabbit will be a buy-out within the next 3 years if they have any success in the clinic with their drugs. I believe the cash on hand should last 3 to 4 years. In addition, Gliadel should bring in more revenues slowly over the next few years. Remember, Amgen's warrants expire in about 3 more years. Whether success or failure, the stock buy back is insignificant in the scheme of things. Look at it this way, they sold the stock at $20/share and they now bought it back at $10/share. When and if they do another drug deal over the next 3 years, the corporate partner will not be buying stock at $10/share, I hope! These guys are savvy business people.